From bench to market, BioAlps provides the opportunities, networks and expertise to ensure that the rich and dense industrial landscape is useful to newcomers and existing players alike. A major advantage is that all the different players are within easy reach. The density of companies in the cluster provides an interesting variety of experience and expertise. The cluster is host to a high number of well-respected industrial firms, multinational corporations and successful small companies.

Key figures at a glance:

  • 935 companies

      • 160 in biotech
      • 410 in medtech
      • 60 in Nutrition & Cosmetics
      • 230 in services
      • 75 associations / Fondations / Venture Capital Funds

  • More than 25’500 employees

Major medtech, pharmaceutical and biotech multinationals are based in the BioAlps cluster. These companies have recognised the benefits that the region offers, namely a tight knit industrial community with expertise in all fields related to their businesses within immediate reach. The companies have either international or European headquarters located within the BioAlps cluster; they bring to the region knowledge, research, business and worldwide renown.

Large companies profit from the research and innovation that start-ups and small companies bring to bear, while the small companies benefit from the knowledge and networks of the larger firms. The aggressive innovation agenda of the BioAlps cluster foster the creation of many new start-ups every year, and the ease of access to finance, legal counsel, R&D expertise is a benefit that many companies use. For the full range of companies, please visit our BioAlps database .

Whatever is needed in the life sciences can be found in the cluster: pharmaceuticals, biotechnology, medical device, diagnostics, nanotechnology and proteomics. Contract manufacturing is available, whether for research, development and manufacturing of chemicals, intermediates, peptides and complex organic molecules, innovative biochemicals, custom synthesis services for fine chemicals. Companies can manufacture active pharmaceutical ingredients (APIs) and biotherapeutics from preclinical to commercial quantities. Contract Research Organisations (CROs) involved in drug and medical device development services provide a portfolio of preclinical and clinical development and commercial service offerings. An existing network of analytical and service laboratories exists with state-of-the-art automation.


Find an actor

BioAlps World Visibitlity Package 201918.03.2019

A yearly international programme for our affiliated companies to increase their visibility.

"Bristol-Myers Squibb to Acquire Celgene for About Billion"

"The combined company will have nine products with more than billion in annual sales"
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn